Abviris GmbH Obtains Almost 3 Million Euros in Series A Financing Abviris GmbH commenced market entry in Germany after successful test-marketing phase (450 customers, 300,000 € revenues) and, respective clinical trials. Initial positioning is targeting screening for HPV induced tumours of head and neck and the anogenital region. Funds raised in round A reveal that…
Read More
A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®. Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal…
Read More
Rochester, MN (USA) / Ahrensburg, Germany: Mayo Clinic and Abviris Deutschland GmbH have successfully signed a cooperation agreement for preclinical research into the diagnostics of HPV induced cancer. Mayo Clinic is one of the leading healthcare and medical research centers of the world. HPV and cancer HPV is responsible for 5% of all cancers, men…
Read More
